Suppr超能文献

肿瘤浸润淋巴细胞联合PD-L1表达对孤立性结直肠癌肝转移患者的预后价值

Prognostic value of tumor infiltrating lymphocytes combined with PD-L1 expression for patients with solitary colorectal cancer liver metastasis.

作者信息

Xiao Binyi, Peng Jianhong, Wang Yongchun, Deng Yuxiang, Ou Qingjian, Wu Xiaojun, Lin Junzhong, Pan Zhizhong, Zhang Lin

机构信息

Department of Colorectal Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine Guangzhou, Guangzhou, China.

Department of Experimental Research, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine Guangzhou, Guangzhou, China.

出版信息

Ann Transl Med. 2020 Oct;8(19):1221. doi: 10.21037/atm-20-2762a.

Abstract

BACKGROUND

The aim of this study was to assess the prognostic value of CD8+ tumor infiltrating lymphocytes (TIL) combined with programmed cell death-ligand 1 (PD-L1) expression for patients with solitary colorectal cancer liver metastasis (SCLM) undergoing R0 resection.

METHODS

Patients undergoing curative hepatectomy for SCLM were reviewed. Immunohistochemical multiplex technique was used for quantifying CD8+ TIL, and immunohistochemical staining was used for assessing PD-L1 expression. The tumor immune microenvironment (TIME) was classified as strong for high CD8+ TIL and low PD-L1, weak for low CD8+ TIL and high PD-L1, and mild for the rest. Recurrence-free survival (RFS) and overall survival (OS) was compared between these groups.

RESULTS

Among the 94 patients included, a high CD8+ TIL and high PD-L1 expression was observed in 51 (54.3%) and 47 (50.0%) patients, respectively. Strong, mild, and weak TIME was observed in 24 (25.5%), 42 (44.7%), and 28 (29.8%) patients, respectively. Patients with a high CD8+ TIL had a significant longer RFS than patients with a low CD8+ TIL (3-year RFS rate, 71.6% 55.3%, P=0.018). The 3-year RFS rate in the strong TIME group was significantly higher than that in the mild and weak TIME groups (89.5% 71.7% and 28.8%, P<0.001), as was the 3-year rate of OS (93.8% 81.8% and 61.6%, P<0.001). CD8+ TIL combined with PD-L1 expression showed better predicting accuracy for RFS than CD8+ TIL alone.

CONCLUSIONS

The density of CD8+ TIL combined with PD-L1 expression in liver metastasis was a predictor of RFS for patients with SCLM undergoing R0 resection, and therefore can be used for guiding the postoperative treatment of these patients.

摘要

背景

本研究旨在评估CD8 +肿瘤浸润淋巴细胞(TIL)联合程序性细胞死亡配体1(PD-L1)表达对接受R0切除的孤立性结直肠癌肝转移(SCLM)患者的预后价值。

方法

回顾性分析接受SCLM根治性肝切除术的患者。采用免疫组织化学多重技术定量CD8 + TIL,并采用免疫组织化学染色评估PD-L1表达。肿瘤免疫微环境(TIME)根据CD8 + TIL高且PD-L1低分为强,CD8 + TIL低且PD-L1高分为弱,其余分为中度。比较这些组之间的无复发生存期(RFS)和总生存期(OS)。

结果

在纳入的94例患者中,分别有51例(54.3%)和47例(50.0%)患者观察到高CD8 + TIL和高PD-L1表达。分别有24例(25.5%)、42例(44.7%)和28例(29.8%)患者观察到强、中、弱TIME。CD8 + TIL高的患者的RFS明显长于CD8 + TIL低的患者(3年RFS率,71.6%对55.3%,P = 0.018)。强TIME组的3年RFS率明显高于中度和弱TIME组(89.5%对71.7%和28.8%,P < 0.001),3年OS率也是如此(93.8%对81.8%和61.6%,P < 0.001)。与单独的CD8 + TIL相比,CD8 + TIL联合PD-L1表达对RFS的预测准确性更高。

结论

肝转移中CD8 + TIL的密度联合PD-L1表达是接受R0切除的SCLM患者RFS的预测指标,因此可用于指导这些患者的术后治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d7b/7607072/ade95301841d/atm-08-19-1221-f1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验